98 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
treatment option for PWS patients.”
Financial Results
Soleno’s current research and development efforts are primarily focused on advancing its lead … of the remaining warrants issued pursuant to the December 2022 Securities Purchase Agreement.
Research and development expenses were $8.7 million
8-K
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
, together with existing cash and cash equivalents, for its current research and development efforts primarily focused on advancing its lead candidate
8-K
EX-10.1
pqloobbxclm
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
o8np6q3rvrvy a6
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
0t7x304 fo1w
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
5u8y58lqiak9 ay
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
gqhra6h 4n
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-10.1
b0y32 zms
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
2u9vgm7ilr1p
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
ji3bqjhh
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
i36wn2
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm